{"id":"second-line-systemic-therapy","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Fatigue"},{"rate":"1-5%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially prolonged survival in patients with certain types of cancer.","oneSentence":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:52.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07113691","phase":"PHASE1","title":"Iadademstat + SBRT With Atezo in ES-SCLC","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-20","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":15},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT06686771","phase":"PHASE3","title":"Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":320},{"nctId":"NCT07490990","phase":"","title":"A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-06","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT06738160","phase":"PHASE2","title":"The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-15","conditions":"NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy","enrollment":27},{"nctId":"NCT05597488","phase":"NA","title":"EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-11-01","conditions":"Cirrhosis Portal","enrollment":160},{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT06813664","phase":"PHASE2","title":"ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-04-01","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease","enrollment":60},{"nctId":"NCT07439328","phase":"NA","title":"ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2024-01-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT07063212","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-07-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer","enrollment":40},{"nctId":"NCT07406646","phase":"NA","title":"Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-11-02","conditions":"Renal Cell Carcinoma, Advanced Kidney Cancer","enrollment":91},{"nctId":"NCT04919122","phase":"","title":"Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2022-04-01","conditions":"Metastatic Renal Cell Carcinoma","enrollment":468},{"nctId":"NCT06486181","phase":"PHASE4","title":"Second Line Endovascular Treatment in Acute DVT","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-04-01","conditions":"Deep Venous Thrombosis","enrollment":100},{"nctId":"NCT03697304","phase":"PHASE2","title":"Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-19","conditions":"Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors","enrollment":211},{"nctId":"NCT06481813","phase":"NA","title":"Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":730},{"nctId":"NCT02715284","phase":"PHASE1","title":"Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2016-03-07","conditions":"Neoplasms","enrollment":730},{"nctId":"NCT03364530","phase":"PHASE2","title":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2018-06-11","conditions":"Cholangiocarcinoma Non-resectable, Non-metastatic","enrollment":40},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT07286643","phase":"NA","title":"Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhosis, Liver, Cirrhotic Cardiomyopathy, Septic Shock","enrollment":140},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07282509","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-12-23","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":116},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT06117891","phase":"","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-11-27","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT04614103","phase":"PHASE2","title":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2021-05-07","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":170},{"nctId":"NCT03468426","phase":"PHASE1","title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-07-05","conditions":"Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms","enrollment":252},{"nctId":"NCT05384626","phase":"PHASE1, PHASE2","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2022-06-09","conditions":"Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":840},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT07162857","phase":"NA","title":"Guiding Fluid Resuscitation in Septic Shock: Ultrasound vs. Noninvasive Cardiac Output Monitoring","status":"COMPLETED","sponsor":"Mai Xiaowei","startDate":"2023-07-05","conditions":"Septic Shock","enrollment":60},{"nctId":"NCT07187284","phase":"PHASE1, PHASE2","title":"EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-09-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":62},{"nctId":"NCT02958852","phase":"PHASE2","title":"A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2025-01-02","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT06753305","phase":"NA","title":"The Effect of Ozone Therapy on Gingivoplasty","status":"RECRUITING","sponsor":"Kutahya Health Sciences University","startDate":"2022-11-15","conditions":"Gingival Enlargement","enrollment":48},{"nctId":"NCT07153952","phase":"PHASE1, PHASE2","title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-01","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy","enrollment":60},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT06841172","phase":"PHASE3","title":"Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-21","conditions":"OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy","enrollment":132},{"nctId":"NCT06033287","phase":"","title":"Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2023-01-01","conditions":"Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors","enrollment":300},{"nctId":"NCT06719362","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2025-06-17","conditions":"Advanced Solid Tumors","enrollment":110},{"nctId":"NCT05797805","phase":"PHASE1, PHASE2","title":"A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Iterion Therapeutics","startDate":"2023-09-13","conditions":"Advanced Hepatocellular Carcinoma","enrollment":178},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03328078","phase":"PHASE1, PHASE2","title":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","status":"RECRUITING","sponsor":"Curis, Inc.","startDate":"2017-12-28","conditions":"Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma","enrollment":152},{"nctId":"NCT06422247","phase":"","title":"Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-04-05","conditions":"Peripheral T-cell Lymphoma","enrollment":307},{"nctId":"NCT06208371","phase":"PHASE3","title":"Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-15","conditions":"Colorectal Neoplasms Malignant","enrollment":117},{"nctId":"NCT05704985","phase":"PHASE1","title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"DEKA Biosciences","startDate":"2023-04-03","conditions":"Cancer, Solid Tumor, Colorectal Cancer","enrollment":39},{"nctId":"NCT05621837","phase":"","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2022-03-10","conditions":"Melanoma, Breast Cancer, Renal Cell Carcinoma","enrollment":1000},{"nctId":"NCT06796543","phase":"NA","title":"Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-03-25","conditions":"Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma","enrollment":70},{"nctId":"NCT04485026","phase":"PHASE2","title":"Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2020-11-04","conditions":"Non Small Cell Lung Cancer, Oligoprogressive","enrollment":""},{"nctId":"NCT06892951","phase":"PHASE1, PHASE2","title":"CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2025-06","conditions":"Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections","enrollment":100},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT05303714","phase":"PHASE3","title":"PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer","status":"RECRUITING","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2022-03-31","conditions":"Oligometastatic Gastric Adenocarcinoma","enrollment":98},{"nctId":"NCT06783348","phase":"PHASE2","title":"Radiopharmaceutical Treatment of Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-10-30","conditions":"Metastatic Clear Cell Renal Cell Carcinoma","enrollment":48},{"nctId":"NCT06503497","phase":"EARLY_PHASE1","title":"A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-07-09","conditions":"Pancreatic Cancer Non-resectable","enrollment":30},{"nctId":"NCT06557967","phase":"","title":"Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2024-03-01","conditions":"Non-small Cell Lung Cancer, Lung Cancer, Metastatic Cancer","enrollment":22517},{"nctId":"NCT05361174","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2022-07-20","conditions":"Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer","enrollment":53},{"nctId":"NCT04450706","phase":"NA","title":"Functional Precision Oncology for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-02-16","conditions":"HER2-negative Breast Cancer","enrollment":15},{"nctId":"NCT03904927","phase":"PHASE2","title":"Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-02-01","conditions":"Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","enrollment":104},{"nctId":"NCT06625359","phase":"PHASE2","title":"High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2015-06-01","conditions":"Central Nervous System Lymphoma","enrollment":17},{"nctId":"NCT06592612","phase":"PHASE2","title":"Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Hepatocellular Carcinoma, Oligoprogression","enrollment":70},{"nctId":"NCT06592287","phase":"PHASE1, PHASE2","title":"The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xianglin Yuan","startDate":"2024-09-30","conditions":"Advanced Gastric Cancer","enrollment":66},{"nctId":"NCT02023086","phase":"","title":"Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients","status":"COMPLETED","sponsor":"Université de Montréal","startDate":"2014-08","conditions":"Fabry Disease","enrollment":8},{"nctId":"NCT06523673","phase":"PHASE3","title":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09","conditions":"Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease","enrollment":104},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT06518018","phase":"","title":"Efficacy and Safety of High-Dose Rate Brachytherapy with Immunotherapy and Chemotherapy As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Neijiang","startDate":"2023-09-01","conditions":"Advanced Stage NSCLC, Second-line Treatment, Patients Without Targetable Driver Mutations","enrollment":80},{"nctId":"NCT06512766","phase":"","title":"a Retrospective Study on the Systemic Treatment of LPP and FFA","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-09-23","conditions":"Cicatricial Alopecia, Lichen Planopilaris, Lichen Plano-Pilaris","enrollment":315},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06413745","phase":"PHASE2","title":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-06-04","conditions":"HER2 Expression / Amplification in Patients With Biliary Tract Cancer","enrollment":65},{"nctId":"NCT06475287","phase":"PHASE2","title":"HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-20","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06441019","phase":"PHASE2","title":"Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab","enrollment":42},{"nctId":"NCT06190782","phase":"PHASE3","title":"Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-27","conditions":"Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy","enrollment":354},{"nctId":"NCT06371586","phase":"PHASE2","title":"Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-03-01","conditions":"Gastric Cancer, Diffuse Type Carcinoma","enrollment":67},{"nctId":"NCT06366932","phase":"PHASE4","title":"Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2023-09-25","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT06285149","phase":"PHASE2","title":"Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2024-03-01","conditions":"HCC","enrollment":80},{"nctId":"NCT05991518","phase":"PHASE1, PHASE2","title":"IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors","status":"UNKNOWN","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2023-04-25","conditions":"HER2 Gene Mutation","enrollment":136},{"nctId":"NCT06213519","phase":"PHASE2","title":"HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-02-20","conditions":"Peritoneal Metastases, Gastric Cancer","enrollment":69},{"nctId":"NCT05315687","phase":"PHASE2","title":"Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2022-08-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver","enrollment":""},{"nctId":"NCT06178146","phase":"PHASE4","title":"Thymosin Alpha-1 for irAE Secondary to ICIs","status":"UNKNOWN","sponsor":"Jun Wang","startDate":"2023-09-01","conditions":"IrAE","enrollment":40},{"nctId":"NCT05364905","phase":"","title":"Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2022-05-09","conditions":"Oncology, Endometrial Cancer, Advanced Cancer","enrollment":200},{"nctId":"NCT05444933","phase":"","title":"A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-09-16","conditions":"Advanced Renal Cell Carcinoma","enrollment":252},{"nctId":"NCT02335944","phase":"PHASE1, PHASE2","title":"Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-01-13","conditions":"Non Small Cell Lung Cancer","enrollment":177},{"nctId":"NCT03586973","phase":"PHASE2","title":"A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-08-06","conditions":"Advanced Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT05062720","phase":"PHASE2","title":"Local Consolidative Therapy in Colorectal Cancer","status":"WITHDRAWN","sponsor":"Fox Chase Cancer Center","startDate":"2021-07-29","conditions":"Colorectal Cancer Metastatic","enrollment":""},{"nctId":"NCT02773485","phase":"PHASE3","title":"Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2015-05","conditions":"Cholangiocarcinoma","enrollment":155},{"nctId":"NCT01033032","phase":"PHASE1, PHASE2","title":"Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-12","conditions":"Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT04037241","phase":"PHASE2, PHASE3","title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-11-01","conditions":"Malignant Tumor of Pancreas Metastatic to Liver","enrollment":""},{"nctId":"NCT01772004","phase":"PHASE1","title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2013-01-31","conditions":"Solid Tumors","enrollment":1756},{"nctId":"NCT05057481","phase":"PHASE3","title":"Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-09-15","conditions":"Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus","enrollment":30},{"nctId":"NCT04998253","phase":"EARLY_PHASE1","title":"Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2","status":"COMPLETED","sponsor":"Unidad Temporal COVID-19 en Centro Citibanamex","startDate":"2020-10-01","conditions":"Hypoxic Pulmonary Vasoconstriction, Hypoxemia, Acute Respiratory Distress Syndrome","enrollment":24},{"nctId":"NCT03093870","phase":"PHASE2, PHASE3","title":"Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2017-07-04","conditions":"Biliary Tract Cancer","enrollment":151},{"nctId":"NCT04852250","phase":"","title":"Centralized Tumour Board and Secondary Intervention Rate in mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-06-01","conditions":"Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication","enrollment":130},{"nctId":"NCT01075048","phase":"PHASE1, PHASE2","title":"ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-01-26","conditions":"Metastatic Colorectal Cancer","enrollment":131},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT03327662","phase":"PHASE3","title":"Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-01-11","conditions":"Adenocarcinoma of the Prostate","enrollment":12},{"nctId":"NCT02912273","phase":"","title":"Optimizing Fall-risk Prediction in Older Adults With Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-10-12","conditions":"Cancer","enrollment":227},{"nctId":"NCT03644511","phase":"","title":"Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment","status":"TERMINATED","sponsor":"Bayer","startDate":"2019-01-24","conditions":"Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT01134341","phase":"PHASE1","title":"Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-03","conditions":"Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome","enrollment":34},{"nctId":"NCT01873352","phase":"PHASE3","title":"Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2013-06-20","conditions":"Atrial Fibrillation, Hypertension","enrollment":302},{"nctId":"NCT03069950","phase":"PHASE2","title":"Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-28","conditions":"Colorectal Adenocarcinoma Metastatic to the Liver","enrollment":""},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT03520257","phase":"PHASE2","title":"The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2018-05-01","conditions":"Hepatocellular Carcinoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":118,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["docetaxel-based chemotherapy","albumin-bound paclitaxel-based chemotherapy","immunotherapy"],"phase":"phase_3","status":"active","brandName":"Second-line systemic therapy","genericName":"Second-line systemic therapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}